Complicanze neurologiche delle malattie internistiche

  • Elio Agostoni
  • Marco Longoni
  • Andrea Rigamonti


Le vasculiti, le connettivopatie e altre malattie immuno-mediate sono disordini sistemici che spesso interessano il sistema nervoso. In alcuni casi i disturbi neurologici possono essere la prima e talvolta l’unica manifestazione di malattia. Una caratteristica comune delle malattie sistemiche è la loro base autoimmune.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Valente RM, Conn DL. Current therapies for systemic vasculitis. Semin Neurol 1994; 14:380–386.CrossRefPubMedGoogle Scholar
  2. 2.
    Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512–1523.CrossRefPubMedGoogle Scholar
  3. 3.
    Hayereth SS. Steroid therapy for visual loss in patients with giant-cell arteritis. Lancet 2000; 355:1572–1573.CrossRefGoogle Scholar
  4. 4.
    Ishikawa K. Effect of prednisone therapy on arterial angiographic features in Takayasu disease. Am J Cardiol 1991; 68:410.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoffmann GS, Leavitt RY, Kerr GS. Treatment of glucocorticosteroid-resistent or relapsing Takayasu arteritis with metotrexate. Arthritis Rheum 1994; 37:578–582.CrossRefGoogle Scholar
  6. 6.
    Moore PM. Vasculitis: diagnosis and therapy. Semin Neurol 1994; 14: 159–167.CrossRefPubMedGoogle Scholar
  7. 7.
    O’Duffy JD. Behçet syndrome. N Engl J Med 1990; 322:326–328.PubMedGoogle Scholar
  8. 8.
    Hamuryudan V, Ozyazgan Y et al. Azathioprine in Behçet syndrome. Arthritis Reum 1997; 40:769.CrossRefGoogle Scholar
  9. 9.
    Calabrese LH. Therapy of systemic vasculitis. Neurologic Clinics 1997; 15:973–991.CrossRefPubMedGoogle Scholar
  10. 10.
    Sabbadini MG. Connettiviti e vasculiti. In: Rugarli C (ed). Terapia medica sistematica. Milano: Masson; 1998:663–678.Google Scholar
  11. 11.
    Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry 1998; 65:10–22CrossRefPubMedGoogle Scholar
  12. 12.
    Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43:8–12.PubMedGoogle Scholar
  13. 13.
    Rob P, Niederstadt C, Reusche E. Dementia in patients undergong long-term dialysis: etiology, differential diagnoses, epidemiology and management. CNS Drugs 2001; 15:691–99CrossRefPubMedGoogle Scholar
  14. 14.
    Hyponatremia. N Engl J Med 2000; 342:1581–1589.Google Scholar
  15. 15.
    Hypernatremia. N Engl J Med 2000; 342:1493–1499.Google Scholar
  16. 16.
    Riggs JE. Neurologic manifestations of fluid and electrolyte disturbances. Neurol Clin 1989; 7:509–523.PubMedGoogle Scholar
  17. 17.
    Samuels MA. Neurologic aspects of hematologic disease. Curr Neurol 1992; 12:215–240.Google Scholar
  18. 18.
    Rock GA, Shumak KH, Buskard NA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393–397.PubMedGoogle Scholar
  19. 19.
    Bell WR, Braine HG, Ness PM. Improved survival in thrombotic thrombocytopenic purpura — emolytic uremic syndrome. N Engl J Med 1991; 325: 398–403.PubMedGoogle Scholar
  20. 20.
    Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484–489.CrossRefPubMedGoogle Scholar
  21. 21.
    Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601–1607.CrossRefPubMedGoogle Scholar
  22. 22.
    Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37 (S1): S32–S42.CrossRefPubMedGoogle Scholar
  23. 23.
    Renaud S, Gregor M, Fuhr P et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27(5): 611–615.CrossRefPubMedGoogle Scholar
  24. 24.
    The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–763.Google Scholar
  25. 25.
    Khamasta MA, Quadrado MJ, Mujik F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholypid-antibody syndrome. N Engl J Med 1995; 332: 993–997.CrossRefGoogle Scholar
  26. 26.
    Rosove MH, Brewer PMC. Antiphospholypid thrombosis: clinical outcome after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–308.PubMedGoogle Scholar
  27. 27.
    Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177–185.PubMedGoogle Scholar
  28. 28.
    Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid sindrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195–207.CrossRefGoogle Scholar
  29. 29.
    Erkan D, Merril JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis of aspirin. Arthritis Rheum 2001; 44: 1466–1467.CrossRefPubMedGoogle Scholar
  30. 30.
    Fleming JL, Wiesner RH, Shorter RG. Whipplès disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc 1988; 63: 539–551.PubMedGoogle Scholar
  31. 31.
    Harper C, Butterworth R. Nutritional and metabolic disorders. In: Graham DI, Lantos PL (eds). Greenfield’s Neuropathology. London: Arnold; 2002: 607–652.Google Scholar
  32. 32.
    Ilniczky S, Jelencsik I, Kenez J, Szirmai I. MRI findings in subacute combined sclerosis of the spinal cord caused by nitrous oxide anaesthesia. Eur J Neurol 2002; 9(1): 101–104.CrossRefPubMedGoogle Scholar
  33. 33.
    Pema PJ, Horak HA, Wyatt RH. Myelopathy caused by nitrous oxide toxicity. Am J Neuroradiol 1998; 19(5): 894–896.PubMedGoogle Scholar
  34. 34.
    Locatelli ER, Laureno R, Ballard P, Mark AS. MRI in vitamin B12 deficiency myelopathy. Can J Neurol Sci 1999; 26: 60–62.PubMedGoogle Scholar
  35. 35.
    Rothenberg SP, da Costa MP, Sequeira JM et al. Autoantibodies against folate receptors in women with pregnancy complicated by a neural-tube defect. N Engl J Med 2004; 350; 2: 134–142.CrossRefPubMedGoogle Scholar
  36. 36.
    Xu Y, Sladtky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology 1989; 39: 1077–1083.PubMedGoogle Scholar
  37. 37.
    Stannus HS HS. Some problems in riboflavine and allied deficiencies. BMJ 1944; ii: 103–5.CrossRefGoogle Scholar
  38. 38.
    Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and MR findings in chronic sensory ganglionopathies. Ann Neurol 2000; 47: 104–109.CrossRefPubMedGoogle Scholar
  39. 39.
    Miller S, Patrick C, Mc Quillen S. et al Abnormal brain development in newborns with congenital heart disease NEJM 2007;357:1928–1938.CrossRefPubMedGoogle Scholar
  40. 40.
    Du Plessis AJ. Neurological complications of cardiac disease in the newborn. Clin. Perinatol 1997;24:807–826.PubMedGoogle Scholar
  41. 41.
    Pallasch J, Takahashi M Taubert KA et al. Association: Endorsed by the Infectious Diseases Society of America Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Complications: A Statement for Healthcare Professionals From the Committee Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Circulation 2005;111;e394–e434.Google Scholar
  42. 42.
    Gage BF, Waterman AD, Shannon W et al Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870.CrossRefPubMedGoogle Scholar
  43. 43.
    Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3Suppl): 429S–456S.CrossRefPubMedGoogle Scholar
  44. 44.
    Fuster V, Ryden LE, Asinger RW, et al. for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the America College of Cardiology/American Heart Association Task Force on ractice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1852–1923.CrossRefPubMedGoogle Scholar
  45. 45.
    Lip GYH. Thromboprophylaxis for atrial fibrillation. Lancet 1999; 353:4–6.CrossRefPubMedGoogle Scholar
  46. 46.
    SPREAD V edizione Ictus cerebrale: linee guida italiane di prevenzione e trattamento Stesura del 2007.Google Scholar
  47. 47.
    Salem DN, Stein PD, Al-Ahmad A et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl):457S–482S.CrossRefPubMedGoogle Scholar
  48. 48.
    Doufekias E, Segal AZ, Kizer JR et al. Cardiogenic and aortogenic brain embolism JACC 2008, 51 (11):1049–1059.PubMedGoogle Scholar
  49. 49.
    Bakhtiar Ali and A. Maziar Zafari Narrative Review: Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Review of the Current Guidelines Ann Intern Med. 2007;147:171–179.Google Scholar
  50. 50.
    Venugopal D, Jhanjee R and Benditt DG, Current Management of Syncope Focus on Drug Therapy Am J Cardiovasc Drugs 2007; 7 (6):99–411.Google Scholar
  51. 51.
    Llinas R, Barbut D, Caplan LR. Neurologic Complications of Cardiac Surgery Progr Cardiov Dis, 2000;Vol. 43, No. 2 (September/October):101–112.Google Scholar
  52. 52.
    Hoffman GM Neurologic Monitoring on Cardiopulmonary Bypass: What Are We Obligated to Do? Ann Thorac Surg 2006;81:S2373–2380.CrossRefPubMedGoogle Scholar
  53. 53.
    Ironside J W. Pituitary gland pathology J Clin Pathol 2003;56:561–568.CrossRefPubMedGoogle Scholar
  54. 54.
    Levy A. Pituitary disease: presentation, diagnosis, and management J Neurol Neurosurg Psychiatry 2004; 75(Suppl III):iii47–iii52.CrossRefPubMedGoogle Scholar
  55. 55.
    Cantalamessa L, Baldini M. Malattie della tiroide. In: Rugarli C (ed). Terapia medica sistematica. Milano: Masson; 1998:595–605.Google Scholar
  56. 56.
    Perros P, Crombie AL, Kendall-Taylor P. Natural hystory of thyroid associated ophtalmopathy. Clin Endocrinol 1995; 42:45–50.CrossRefGoogle Scholar
  57. 57.
    Bartalera L, Marcucci C, Bogazzi F. Relation between therapy for hyperthyroidism and the course of Gravès ophtalmopaty. N Engl J Med 1998; 338:73–78.CrossRefGoogle Scholar
  58. 58.
    Ferracci F, Moretto G, Candeago RM et al. Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004; 217(2):165–168.CrossRefPubMedGoogle Scholar
  59. 59.
    Ferracci F, Moretto G, Candeago RM et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology 2003; 60(4):712–714.PubMedGoogle Scholar
  60. 60.
    Drucker AJ, Nauck MA, The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006; 368: 1696–1705.CrossRefPubMedGoogle Scholar
  61. 61.
    Fujioka M, Okuchi K, Hiramatsu KI et al. Specific changes in human brain after hypoglycemic injury. Stroke 1997; 28:584–587.PubMedGoogle Scholar
  62. 62.
    Ahya SN., Flood K, Paranjothi S. Washington Manuale di Terapia 30° Edizione Centro Scientifico Editore.Google Scholar
  63. 63.
    Weissenborn K, Bokemeyer M, Krause J et al Neurological and neuropsychiatric syndromes associated with liver disease AIDS 2005, 19 (suppl 3):S93–S98.CrossRefPubMedGoogle Scholar
  64. 64.
    Shawcross D, Jalan R Dispelling myths in the treatment of hepatic encephalopathy Lancet 2005; 365: 431–433.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Elio Agostoni
    • 1
  • Marco Longoni
    • 1
  • Andrea Rigamonti
    • 1
  1. 1.Dipartimento di Neuroscienze Struttura Complessa di Neurologia — Stroke UnitAzienda Ospedaliera “Ospedale di Lecco”Lecco

Personalised recommendations